|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
|
ATE375363T1
(de)
|
1997-07-14 |
2007-10-15 |
Bolder Biotechnology Inc |
Derivate des wachstumshormons und verwandte proteine
|
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US7153943B2
(en)
*
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
|
US7495087B2
(en)
*
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
|
US6677433B2
(en)
*
|
1999-01-27 |
2004-01-13 |
The Regents Of The University Of California |
Stabilization of hypoallergenic, hyperdigestible previously reduced proteins
|
|
KR100356140B1
(ko)
*
|
1999-07-08 |
2002-10-19 |
한미약품공업 주식회사 |
인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
|
|
NZ522847A
(en)
*
|
2000-05-16 |
2004-11-26 |
Bolder Biotechnology Inc |
Methods for refolding proteins containing free cysteine residues
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
EP1314739A1
(en)
*
|
2001-11-22 |
2003-05-28 |
Bayer Ag |
Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
|
|
AU2003219922B2
(en)
|
2002-02-27 |
2009-09-10 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials, and methods of making and using the same
|
|
US7635463B2
(en)
|
2002-02-27 |
2009-12-22 |
Pharmain Corporation |
Compositions for delivery of therapeutics and other materials
|
|
EP1490402A4
(en)
|
2002-03-20 |
2007-05-02 |
Biopolymed Inc |
PREPARATION OF CYSTEINREST STOCHIOMETRIC WITH BIOKOMPATIBLE POLYMER CONJUGATED G-CSF
|
|
WO2004022593A2
(en)
*
|
2002-09-09 |
2004-03-18 |
Nautilus Biotech |
Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
|
|
US8129330B2
(en)
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
|
US7314613B2
(en)
|
2002-11-18 |
2008-01-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
|
GEP20084486B
(en)
|
2002-12-26 |
2008-09-25 |
Mountain View Pharmaceuticals |
Polymer conjugates of interferon-beta with enhanced biological potency
|
|
KR101031206B1
(ko)
|
2002-12-31 |
2011-04-27 |
넥타르 테라퓨틱스 |
말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
|
|
EP1596887B1
(en)
|
2003-02-26 |
2022-03-23 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
|
US7587286B2
(en)
|
2003-03-31 |
2009-09-08 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
|
CA2522345A1
(en)
|
2003-04-09 |
2004-11-18 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
EP1613274B1
(en)
|
2003-04-15 |
2010-03-03 |
GlaxoSmithKline LLC |
Human il-18 substitution mutants and their conjugates
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
EP1675871A2
(en)
|
2003-10-10 |
2006-07-05 |
Xencor Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
ES2422187T3
(es)
*
|
2003-12-03 |
2013-09-09 |
Biogenerix Ag |
Factor estimulante de colonias de granulocitos glicopegilados
|
|
EP1699920A4
(en)
*
|
2003-12-31 |
2008-05-28 |
Centocor Inc |
NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL
|
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
|
WO2005113592A2
(en)
|
2004-05-19 |
2005-12-01 |
Maxygen, Inc. |
Interferon-alpha polypeptides and conjugates
|
|
JP5014988B2
(ja)
*
|
2004-07-16 |
2012-08-29 |
マイクロメット アクツィエン ゲゼルシャフト |
発現増強ポリペプチド
|
|
WO2006019950A2
(en)
*
|
2004-07-16 |
2006-02-23 |
Nektar Therapeutics Al, Corporation |
Conjugates of a gm-csf moiety and a polymer
|
|
CN101043899B
(zh)
|
2004-08-19 |
2011-03-30 |
比奥根艾迪克Ma公司 |
重折叠转化型生长因子beta家族蛋白
|
|
DE102004041639A1
(de)
*
|
2004-08-27 |
2006-03-02 |
Bioceuticals Arzneimittel Ag |
Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies
|
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
US7998930B2
(en)
|
2004-11-04 |
2011-08-16 |
Hanall Biopharma Co., Ltd. |
Modified growth hormones
|
|
CA2593682C
(en)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
US7678578B2
(en)
*
|
2005-02-07 |
2010-03-16 |
Beckman Coulter, Inc. |
Cell permeabilization and stabilization reagent and method of use
|
|
US9187546B2
(en)
|
2005-04-08 |
2015-11-17 |
Novo Nordisk A/S |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
|
CA2607651A1
(en)
|
2005-05-18 |
2007-04-19 |
Maxygen, Inc. |
Evolved interferon-alpha polypeptides
|
|
KR100694994B1
(ko)
*
|
2005-06-13 |
2007-03-14 |
씨제이 주식회사 |
사람 과립구 콜로니 형성인자 동종체
|
|
US8633300B2
(en)
|
2005-06-17 |
2014-01-21 |
Novo Nordisk Healthcare Ag |
Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
|
|
DE102005033250A1
(de)
|
2005-07-15 |
2007-01-18 |
Bioceuticals Arzneimittel Ag |
Verfahren zur Reinigung von G-CSF
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
US20090048440A1
(en)
|
2005-11-03 |
2009-02-19 |
Neose Technologies, Inc. |
Nucleotide Sugar Purification Using Membranes
|
|
MY143274A
(en)
|
2005-12-22 |
2011-04-15 |
Genentech Inc |
Recombinant production of heparin binding proteins
|
|
CN100475270C
(zh)
*
|
2006-01-20 |
2009-04-08 |
清华大学 |
一种治疗肿瘤的药物及其应用
|
|
TWI501774B
(zh)
|
2006-02-27 |
2015-10-01 |
Biogen Idec Inc |
神經性病症之治療
|
|
DE102006009437A1
(de)
|
2006-03-01 |
2007-09-13 |
Bioceuticals Arzneimittel Ag |
G-CSF-Flüssigformulierung
|
|
GB0605684D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Sicor Biotech Uab |
Method For Purifying Granulocyte-Colony Stimulating Factor
|
|
CN101045742B
(zh)
*
|
2006-03-27 |
2011-12-21 |
华北制药集团新药研究开发有限责任公司 |
重组人粒细胞集落刺激因子的复性纯化工艺
|
|
US20080096819A1
(en)
*
|
2006-05-02 |
2008-04-24 |
Allozyne, Inc. |
Amino acid substituted molecules
|
|
AU2007253264A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Novo Nordisk Health Care Ag |
Factor IX analogues having prolonged in vivo half life
|
|
CN101506222B
(zh)
|
2006-07-14 |
2013-10-02 |
健泰科生物技术公司 |
重组蛋白的重折叠
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
DE602007009995D1
(de)
*
|
2006-08-01 |
2010-12-02 |
Pieris Ag |
Muteine von tearlipocalin und verfahren zu deren gewinnung
|
|
US8969532B2
(en)
|
2006-10-03 |
2015-03-03 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
|
|
US8617531B2
(en)
|
2006-12-14 |
2013-12-31 |
Bolder Biotechnology, Inc. |
Methods of making proteins and peptides containing a single free cysteine
|
|
AU2012203658B2
(en)
*
|
2007-01-10 |
2014-05-08 |
Protgen Ltd. |
Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
|
|
CN101219219B
(zh)
*
|
2007-01-10 |
2013-02-13 |
北京普罗吉生物科技发展有限公司 |
包含血管抑素或其片段的复合物、其制备方法及应用
|
|
EP2144923B1
(en)
|
2007-04-03 |
2013-02-13 |
BioGeneriX AG |
Methods of treatment using glycopegylated g-csf
|
|
TWI445544B
(zh)
|
2007-05-01 |
2014-07-21 |
Biogen Idec Inc |
增進血管形成之組合物及方法
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
US8546328B2
(en)
|
2007-08-27 |
2013-10-01 |
Biogenerix Ag |
Liquid formulation of G-CSF conjugate
|
|
WO2009058203A1
(en)
*
|
2007-10-29 |
2009-05-07 |
Albert Einstein College Of Medicine Of Yeshiva University |
Radiolabeled monoclonal antibodies, methods of preparation using tcep, and uses thereof
|
|
CA2710841C
(en)
*
|
2007-12-29 |
2018-01-23 |
Biosteed Gene Expression Tech. Co., Ltd. |
Y-shaped polyethylene glycol modified g-csf, the preparation and use thereof
|
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
|
US20130189239A1
(en)
|
2008-02-27 |
2013-07-25 |
Novo Nordisk A/S |
Conjugated Factor VIII Molecules
|
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
|
UA99339C2
(ru)
*
|
2008-03-12 |
2012-08-10 |
Имклоун Ллк |
Антитело, которое специфично связывает человеческий tyrp1
|
|
WO2009128917A2
(en)
|
2008-04-14 |
2009-10-22 |
Halozyme, Inc. |
Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
CN102307993B
(zh)
|
2008-12-09 |
2014-06-25 |
哈洛齐梅公司 |
延长的可溶性ph20多肽及其用途
|
|
SG176963A1
(en)
|
2009-06-22 |
2012-02-28 |
Amgen Inc |
Refolding proteins using a chemically controlled redox state
|
|
LT3660032T
(lt)
|
2009-06-25 |
2026-02-25 |
Amgen Inc. |
Ne žinduolių sistemoje ekspresuotų baltymų surišamojo gryninimo būdai
|
|
PT2477603E
(pt)
|
2009-09-17 |
2016-06-16 |
Baxalta Inc |
Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
|
|
PL2525834T3
(pl)
|
2010-01-22 |
2020-10-19 |
Novo Nordisk Health Care Ag |
Hormony wzrostu o przedłużonej skuteczności in-vivo
|
|
RU2012134974A
(ru)
*
|
2010-01-22 |
2014-02-27 |
Ново Нордиск Хелс Кеа Аг |
Стабилизированное соединение гормона роста
|
|
BR112012022518A2
(pt)
|
2010-03-17 |
2020-10-13 |
Biogenerix Gmbh |
método para obtenção de g- csf recombinante humano biologicamente ativo
|
|
DK2595624T3
(en)
|
2010-07-20 |
2018-03-26 |
Halozyme Inc |
Methods of treating or preventing adverse side effects associated with administration of an anti-hyaluronan agent
|
|
WO2012064867A1
(en)
*
|
2010-11-09 |
2012-05-18 |
Nektar Therapeutics |
Pharmacologically active polymer-g-csf conjugates
|
|
CA2826114A1
(en)
*
|
2011-02-01 |
2012-08-09 |
Fate Therapeutics, Inc. |
Cardiotrophin related molecules for enhanced therapeutics
|
|
EP2907504B1
(en)
|
2011-02-08 |
2017-06-28 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
|
SG194780A1
(en)
|
2011-05-05 |
2013-12-30 |
Wellstat Immunotherapeutics Llc |
Complement factor b analogs and their uses
|
|
US9320777B2
(en)
|
2011-05-13 |
2016-04-26 |
Bolder Biotechnology, Inc. |
Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
|
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
|
US20130022592A1
(en)
|
2011-06-17 |
2013-01-24 |
Daniel Edward Vaughn |
Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
|
|
US20130071394A1
(en)
|
2011-09-16 |
2013-03-21 |
John K. Troyer |
Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
|
|
CA2853358A1
(en)
|
2011-10-24 |
2013-05-02 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
|
SG11201403714TA
(en)
|
2011-12-30 |
2014-07-30 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
|
HUP1200172A2
(en)
|
2012-03-19 |
2013-10-28 |
Richter Gedeon Nyrt |
Methods for refolding g-csf from inclusion bodies
|
|
HUP1200171A1
(hu)
|
2012-03-19 |
2013-09-30 |
Richter Gedeon Nyrt |
Módszerek polipeptidek elõállítására
|
|
EP2833905B1
(en)
|
2012-04-04 |
2018-05-02 |
Halozyme, Inc. |
Combination therapy with hyaluronidase and a tumor-targeted taxane
|
|
TR201910573T4
(tr)
|
2012-08-31 |
2019-08-21 |
Glaxosmithkline Biologicals Sa |
Staphylococcus aureus'a karşı bağışıklık kazandırmak için stabilize edilmiş proteinler.
|
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
|
EP2920204B1
(en)
*
|
2012-11-16 |
2019-09-18 |
IBA GmbH |
Streptavidin muteins and methods of using them
|
|
ES2841123T3
(es)
|
2013-04-05 |
2021-07-07 |
Formulacion Del Compuesto De La Hormona De Crecimiento |
Formulación del compuesto de la hormona de crecimiento
|
|
JP2016526014A
(ja)
*
|
2013-04-24 |
2016-09-01 |
アルモ・バイオサイエンシーズ・インコーポレイテッド |
インターロイキン−１０組成物及びその使用
|
|
WO2015000585A1
(en)
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ｐｈ２０玻尿酸酶變異體及其用途
|
|
EP3079722B1
(en)
*
|
2013-12-13 |
2021-03-24 |
Novo Nordisk Health Care AG |
Method for thioether conjugation of proteins
|
|
CN103992400B
(zh)
*
|
2014-05-29 |
2017-01-04 |
江苏吴中医药集团有限公司苏州中凯生物制药厂 |
重组人血管内皮抑素的复性液及其制备、使用方法
|
|
US10457716B2
(en)
|
2014-08-06 |
2019-10-29 |
University Of Notre Dame Du Lac |
Protein folding and methods of using same
|
|
EP3186281B1
(en)
|
2014-08-28 |
2019-04-10 |
Halozyme, Inc. |
Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
|
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
|
US11229683B2
(en)
|
2015-09-18 |
2022-01-25 |
Bolder Biotechnology, Inc. |
Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
|
|
PE20200697A1
(es)
|
2017-06-22 |
2020-06-16 |
Catalyst Biosciences Inc |
Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
|
|
WO2019222435A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
|
JP7604376B2
(ja)
|
2018-12-28 |
2024-12-23 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
|
|
MX2022001975A
(es)
|
2019-08-16 |
2022-03-11 |
Applied Molecular Transport Inc |
Composiciones, formulaciones y produccion y purificacion de interleucinas.
|
|
CN115968291A
(zh)
*
|
2020-04-22 |
2023-04-14 |
南湖制药公司 |
聚乙二醇化干扰素tau及其组合物和方法
|
|
CN114763542A
(zh)
*
|
2021-01-12 |
2022-07-19 |
正大天晴药业集团股份有限公司 |
利用酵母胞内表达制备黄曲霉尿酸氧化酶的方法
|
|
WO2025227129A2
(en)
|
2024-04-25 |
2025-10-30 |
Starrock Pharma Llc |
Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
|
|
US20250341516A1
(en)
|
2024-05-01 |
2025-11-06 |
BioLegend, Inc. |
Compositions for use with multiple fluorophores and methods of using
|